Pingtung Hospital, Ministry of Health and Welfare, Pingtung 90054, Taiwan.
Department of Surgery, Faculty of Medicine, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.
Cells. 2022 Nov 23;11(23):3744. doi: 10.3390/cells11233744.
Despite the implementation of global screening programs, colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide. More than 10% of patients with colon cancer are diagnosed as having locally advanced disease with a relatively poor five-year survival rate. Locally advanced colon cancer (LACC) presents surgical challenges to R0 resection. The advantages and disadvantages of preoperative radiotherapy for LACC remain undetermined. Although several reliable novel biomarkers have been proposed for the prediction and prognosis of CRC, few studies have focused solely on the treatment of LACC. This comprehensive review highlights the role of predictive biomarkers for treatment and postoperative oncological outcomes for patients with LACC. Moreover, this review discusses emerging needs and approaches for the discovery of biomarkers that can facilitate the development of new therapeutic targets and surveillance of patients with LACC.
尽管实施了全球筛查计划，结直肠癌（CRC）仍然是全球癌症相关死亡的第二大主要原因。超过 10%的结肠癌患者被诊断为局部晚期疾病，五年生存率相对较差。局部晚期结肠癌（LACC）对 R0 切除提出了手术挑战。术前放疗治疗 LACC 的优缺点仍未确定。尽管已经提出了一些可靠的新型生物标志物用于预测和预后 CRC，但很少有研究专门针对 LACC 的治疗。本综述重点介绍了预测生物标志物在治疗和 LACC 患者术后肿瘤学结局中的作用。此外，本综述还讨论了发现有助于开发新的治疗靶点和监测 LACC 患者的生物标志物的新需求和方法。
